HRP20080313A2 - Metode poboljšanja farmakokinetičkih svojstava inhibitora hiv integraze - Google Patents

Metode poboljšanja farmakokinetičkih svojstava inhibitora hiv integraze

Info

Publication number
HRP20080313A2
HRP20080313A2 HR20080313A HRP20080313A HRP20080313A2 HR P20080313 A2 HRP20080313 A2 HR P20080313A2 HR 20080313 A HR20080313 A HR 20080313A HR P20080313 A HRP20080313 A HR P20080313A HR P20080313 A2 HRP20080313 A2 HR P20080313A2
Authority
HR
Croatia
Prior art keywords
improving
hiv integrase
pharmacokinetics
methods
integrase inhibitors
Prior art date
Application number
HR20080313A
Other languages
English (en)
Inventor
P. Kearney Brian
Kakee Atsuyuki
Kawaguchi Isao
Original Assignee
Gilead Sciences
Japan Tobacco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Japan Tobacco filed Critical Gilead Sciences
Publication of HRP20080313A2 publication Critical patent/HRP20080313A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Izum prikazuje metode poboljšanja farmakokinetilčkih svojstava inhibitora integraze HIV davanjem hrane i ritonavira ili njegovom farmaceutski prihvatljivu sol s inhibitorom integraze HIV.
HR20080313A 2005-12-30 2008-07-01 Metode poboljšanja farmakokinetičkih svojstava inhibitora hiv integraze HRP20080313A2 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US75663106P 2006-01-06 2006-01-06
US76390106P 2006-02-01 2006-02-01
PCT/US2006/049668 WO2007079260A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
HRP20080313A2 true HRP20080313A2 (hr) 2008-11-30

Family

ID=38016698

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080313A HRP20080313A2 (hr) 2005-12-30 2008-07-01 Metode poboljšanja farmakokinetičkih svojstava inhibitora hiv integraze

Country Status (16)

Country Link
US (1) US20070219243A1 (hr)
EP (2) EP2308490A1 (hr)
JP (1) JP4676536B2 (hr)
KR (3) KR20160074018A (hr)
CN (1) CN104069108A (hr)
AP (1) AP2702A (hr)
AU (1) AU2006332664B2 (hr)
BR (1) BRPI0620865A2 (hr)
CA (2) CA2635468C (hr)
EA (2) EA018544B1 (hr)
HR (1) HRP20080313A2 (hr)
IL (1) IL192208A (hr)
NO (1) NO20083333L (hr)
NZ (1) NZ569576A (hr)
SG (2) SG170796A1 (hr)
WO (1) WO2007079260A1 (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
LT2487162T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
AP2490A (en) * 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
BRPI0813000A2 (pt) * 2007-06-29 2014-12-23 Gilead Sciences Inc Composições terapêuticas e uso das mesmas
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
AU2011209788C1 (en) * 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
MX357940B (es) 2012-12-21 2018-07-31 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
SI3252058T1 (sl) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV
NO2865735T3 (hr) 2013-07-12 2018-07-21
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (hr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
EP3736274A1 (en) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PL3346995T3 (pl) 2015-11-09 2020-03-31 Gilead Sciences, Inc. Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
ATE143262T1 (de) 1992-12-29 1996-10-15 Abbott Lab Inhibitoren der retroviralen protease
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
SI1183026T1 (sl) * 1999-06-04 2006-10-31 Abbott Lab Izboljsane farmacevtske spojine, vsebujoce ritonavir
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EP3406596A1 (en) * 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
BRPI0407052A (pt) * 2003-01-27 2006-01-17 Pfizer Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização
WO2004101512A2 (en) * 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
NZ563361A (en) * 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP5221544B2 (ja) * 2006-09-12 2013-06-26 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
BRPI0813000A2 (pt) * 2007-06-29 2014-12-23 Gilead Sciences Inc Composições terapêuticas e uso das mesmas
AP2490A (en) * 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Also Published As

Publication number Publication date
AU2006332664B2 (en) 2013-03-14
CA2847871A1 (en) 2007-07-12
BRPI0620865A2 (pt) 2011-11-29
CA2635468C (en) 2016-08-09
SG170795A1 (en) 2011-05-30
NO20083333L (no) 2008-09-29
US20070219243A1 (en) 2007-09-20
SG170796A1 (en) 2011-05-30
IL192208A (en) 2013-10-31
WO2007079260A1 (en) 2007-07-12
AP2702A (en) 2013-07-23
EA201201496A1 (ru) 2013-07-30
KR20140082858A (ko) 2014-07-02
WO2007079260A9 (en) 2007-08-30
KR20080081358A (ko) 2008-09-09
EA018544B1 (ru) 2013-08-30
KR20160074018A (ko) 2016-06-27
CN104069108A (zh) 2014-10-01
JP4676536B2 (ja) 2011-04-27
EP1976517A1 (en) 2008-10-08
AU2006332664A1 (en) 2007-07-12
JP2009525265A (ja) 2009-07-09
CA2847871C (en) 2016-07-26
KR101524165B1 (ko) 2015-06-01
IL192208A0 (en) 2009-02-11
CA2635468A1 (en) 2007-07-12
NZ569576A (en) 2011-09-30
AP2008004522A0 (en) 2008-06-30
EP2308490A1 (en) 2011-04-13
EA200801619A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
HRP20080313A2 (hr) Metode poboljšanja farmakokinetičkih svojstava inhibitora hiv integraze
CY1122777T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
NO20064555L (no) HIV-integraseinhibitorer.
ATE534645T1 (de) Kaliumsalz eines hiv-integrasehemmers
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
MX2015011778A (es) Combinacion de farmaco.
TN2009000446A1 (en) P70 s6 kinase inhibitors
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
RS52979B (en) INHIBITORI P38 MAP KINAZE
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
EA200801199A1 (ru) Ингибиторы киназы
ATE495176T1 (de) Spiroindolinon-derivate
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
DE602006016231D1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
ZA200706306B (en) Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
FR2924118B1 (fr) Fragments d'anticorps inhibiteurs de la proteine nef du vih.
ATE429921T1 (de) 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
CY1116189T1 (el) Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
TW200716581A (en) Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2019074464A3 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
CY1119482T1 (el) Ιμιδαζολκαρβοξαμιδια και χρηση αυτων ως αναστολεις του faah
CY1114113T1 (el) Συνδυασμος ενος αναστολεα του κολπικου ρευματος if και ενος βητα-αναστολεα

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20171214

Year of fee payment: 12

ODBC Application rejected